This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Uh Oh Arena Pharma! Q3 Belviq Sales Just $4.8M

SAN DIEGO ( TheStreet) -- The launch of Arena Pharmaceuticals' (ARNA - Get Report) obesity pill Belviq is foundering. Third quarter net sales totaled a tiny $4.8 million, well below even reduced Wall Street expectations.

Early Friday morning, Eisai -- Arena's marketing partner for Belviq -- reported $9 million in Belviq net sales for the six months period ended June 30.

Important to note: That's $9 million of Belviq sold over the past two quarters. Arena and Eisai announced the commercial launch of the obesity pill during the first week of June.

Last August, Eisai reported second quarter Belviq net sales of $4.2 million, representing three weeks of sales in June.

That means for the entire third quarter, Belviq sales totaled $4.8 million. A new drug that manages to generate just 14% sales growth over the first two quarters of its launch is on a dismal trajectory.

Arena receives 31.5% royalty on Belviq net sales, so the company should report third quarter revenue of approximately $1.5 million -- well below Street consensus expectations of $5.5 million. Arena reports third-quarter results on Nov. 7.

Eisai announced recently plans to double to 400 the number of U.S. sales reps marketing Belviq. Now we know why. ARNA Chart ARNA data by YCharts

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.57 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $154.71 -12.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs